Harrow Inc
HROW
View Detailed Chart
38.790USD
+0.220+0.57%
Close 08/27, 16:00（ET）Quotes delayed by 15 min
1.42BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.57%
5 Days
+1.46%
1 Month
+7.18%
6 Months
+40.75%
Year to Date
+15.62%
1 Year
-10.62%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-08-27Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite a very weak market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
8
analysts
Buy
Current Rating
59.829
Target Price
+55.12%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.31% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.10.
Undervalued
The company’s latest PE is -139.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.63M shares, decreasing 10.09% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.95M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMr. John P. Saharek
Websitehttps://www.harrow.com/
Related Instruments
-0.25%
+0.17%
-0.14%
-0.15%
+0.20%
-1.08%
+1.99%
-0.56%
+0.60%
-0.72%
-0.38%
+0.49%
+0.89%
+0.83%
+0.44%
+0.20%
+0.10%
+0.37%
-0.12%
+0.66%
